Konstantin Severinov, New Brunswick, NJ (US); Feng Zhang, Cambridge, MA (US); Yuri I. Wolf, Bethesda, MD (US); Sergey Shmakov, Moscow (RU); Ekaterina Semenova, New Brunswick, NJ (US); Leonid Minakhin, New Brunswick, NJ (US); Kira S. Makarova, Bethesda, MD (US); Eugene Koonin, Bethesda, MD (US); Silvana Konermann, Cambridge, MA (US); Julia Joung, Cambridge, MA (US); Jonathan S. Gootenberg, Cambridge, MA (US); Omar O. Abudayyeh, Cambridge, MA (US); and Eric S. Lander, Cambridge, MA (US)
Assigned to The Broad Institute, Inc., Cambridge, MA (US); Massachusetts Institute of Technology, Cambridge, MA (US); President and Fellows of Harvard College, Cambridge, MA (US); Rutgers, the State University of New Jersey, New Brunswick, NJ (US); Skolkovo Institute of Science and Technology, Moscow (RU); and The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed by The Broad Institute, Inc., Cambridge, MA (US); Massachusetts Institute of Technology, Cambridge, MA (US); President and Fellows of Harvard College, Cambridge, MA (US); Rutgers, The State University of New Jersey, New Brunswick, NJ (US); Skolkovo Institute of Science and Technology, Moscow Region (RU); and The United States of America, as represented by the Secretary, Dept. of Health and Human Services, Bethesda, MD (US)
Filed on Jun. 24, 2022, as Appl. No. 17/848,563.
Application 17/848,563 is a division of application No. 15/844,530, filed on Dec. 16, 2017, granted, now 11,421,250.
Application 15/844,530 is a continuation in part of application No. PCT/US2016/038258, filed on Jun. 17, 2016.
Claims priority of provisional application 62/320,231, filed on Apr. 8, 2016.
Claims priority of provisional application 62/296,522, filed on Feb. 17, 2016.
Claims priority of provisional application 62/285,349, filed on Oct. 22, 2015.
Claims priority of provisional application 62/181,675, filed on Jun. 18, 2015.
Prior Publication US 2022/0372525 A1, Nov. 24, 2022
1. A non-naturally occurring or engineered composition comprising a Type VI Cas polypeptide comprising two higher eukaryotes and prokaryotes nucleotide binding (HEPN) domains and one or more nucleic acid component(s), wherein the one or more nucleic acid components are capable of forming a CRISPR-Cas complex with the Cas polypeptide and of directing sequence-specific binding of said complex to a target sequence of a polynucleotide in a eukaryotic cell.